Altimmune, Inc. (ALT)
NASDAQ: ALT · Real-Time Price · USD
4.780
+0.035 (0.74%)
At close: Apr 2, 2025, 4:00 PM
4.699
-0.082 (-1.71%)
After-hours: Apr 2, 2025, 6:26 PM EDT
Altimmune Revenue
In the year 2024, Altimmune had annual revenue of $20.00K, down -95.31%. Altimmune had revenue of $5.00K in the quarter ending December 31, 2024, a decrease of -86.49%.
Revenue (ttm)
$20.00K
Revenue Growth
-95.31%
P/S Ratio
18,406.26
Revenue / Employee
$339
Employees
59
Market Cap
368.13M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 20.00K | -406.00K | -95.31% |
Dec 31, 2023 | 426.00K | 494.00K | -726.47% |
Dec 31, 2022 | -68.00K | -4.48M | -101.54% |
Dec 31, 2021 | 4.41M | -3.78M | -46.12% |
Dec 31, 2020 | 8.19M | 2.38M | 41.09% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
ALT News
- 16 days ago - Altimmune: Pemvidutide Differentiation Advancement In MASH Space Continues To Shine - Seeking Alpha
- 20 days ago - Altimmune to test obesity drug for alcohol use disorder and related health conditions - Reuters
- 27 days ago - Altimmune to Host Virtual R&D Day on March 13, 2025 - GlobeNewsWire
- 4 weeks ago - Altimmune to Participate in the Leerink Global Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Altimmune Q4 Earnings Review: The Big News Is The MASH With Obesity Data Readout Due Q2 - Seeking Alpha
- 4 weeks ago - Altimmune, Inc. (ALT) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Altimmune Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update - GlobeNewsWire
- 5 weeks ago - Seasoned Biopharmaceutical Industry Executives Teri Lawver and Jerry Durso Appointed to Altimmune Board of Directors - GlobeNewsWire